Issue Date: August 28, 2017
Samsung, Takeda team for new biologics
Samsung Bioepis and Takeda Pharmaceutical are joining to develop new biologic therapies for areas of unmet medical need. The partners’ first program is TAK-671, a treatment for pancreatitis. Samsung Bioepis launched in 2012 as a manufacturer of the generic biologic drugs known as biosimilars. “Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” says CEO Christopher Hansung Ko.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society